Category: Shire Plc.
Ireland-based Shire plc signs a definitive agreement to divest its beleaguered Dermagraft skin substitute, handing the business over to Organogenesis in a deal worth up to $300 million.
Regenerative therapies maker Shire (NSDQ:SHPGY) announced that it sold its troubled Dermagraft business to Organogenesis in a deal worth up to $300 million in sales-based milestone payments.
Massachusetts Institute of Technology and Children's Hospital Corp. accuse Shire Regenerative Medicine of willfully infringing on a trio of patents with its DermaGraft diabetic foot ulcer skin graft treatment.
Regenerative therapies maker Shire (NSDQ:SHPGY) found itself the focus of a lawsuit after the Massachusetts Institute of Technology and Children's Medical Center Corp. accused the company of willfully infringing on a trio of patents.
British pharma player Shire expands its regenerative medicine footprint with the acquisition of Lotus Tissue Repair, which focuses on the treatment of the genetic disease dystrophic epidermolysis bullosa.
Shire (NSDQ:SHPGY) said it aquired Cambridge, Mass.-based Lotus Tissue Repair, which is developing the 1st protein replacement therapy to treat dystrophic epidermolysis bullosa, a rare genetic disease.
The purchase includes an upfront payment and later milestone payments, but specific details were not released.
Health Canada approves the DermaGraft regenerative skin patch for patients with diabetic foot ulcers.
Regulators north of the border gave Shire (NSDQ:SHPGY) its first approval outside of the U.S. for the DermaGraft regenerative skin patch it bought when it acquired Advanced BioHealing last year.
Venture-backed "Big Exits" in the medical device industry were higher in 2011 than for the 4 years prior.
Venture-backed M&A activity in 2011 was higher than any other year since 2005, according to a new report tracking trends in lifesciences.
The medical device industry in 2011 had 18 "Big Exits," defined as venture-backed acquisitions where the up-front payment totaled $75 million or more.
Shire puts more skin in regenerative medicine with a $100 million facility expansion in San Diego that it hopes will turn into a billion-dollar business within the decade.
Shire (NSDQ:SHPGY) has high hopes for its regenerative medicine units, aiming to forge a $1 billion business within the decade.
Shire faces civil and criminal investigations by the U.S. Justice Dept. and a pair of U.S. Attorneys' Offices for marketing practices related to its DermaGraft diabetic foot ulcer treatment.
British biotech Shire (NSDQ:SHPGY) is under investigation by the U.S. Justice Dept. for marketing practices for its Dermagraft diabetic foot ulcer treatment, according to regulatory filings.